title: Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment.
abstract: The susceptibility of the established cultured gliosarcoma line GI-1 to lymphokine-activated killer (LAK) cells was analyzed with and without interferon (IFN)-gamma treatment of target GI-1 cells. IFN-gamma treatment decreased the susceptibility of GI-1 cells to LAK cell cytolysis in a dose-dependent manner. Acid treatment of GI-1 cells increased their susceptibility to cytolysis compared with untreated cells. IFN-gamma treatment and acid treatment of GI-1 cells respectively increased and decreased the expression of class I HLA antigens on GI-1 cells. The susceptibility of GI-1 cells to LAK cell cytolysis and their expression of HLA class I molecules were inversely correlated. Subpopulation depletion experiments on the LAK cells with monoclonal antibodies and complement revealed that phenotypically natural killer type (CD16+) cells had a high cytotoxic activity against untreated GI-1 cells but a relatively low activity against IFN-gamma-treated GI-1 cells in both the precursor and effector phases. On the other hand, phenotypically T-type (CD3+) cells did not show these tendencies at all in both the precursor and the effector phases.
authors: Department of Neurosurgery, Faculty of Medicine, Kyoto University, Japan.
authors: S
authors: S
authors: Miyatake
authors: H
authors: H
authors: Kikuchi
authors: Y
authors: Y
authors: Oda
authors: T
authors: T
authors: Nishioka
authors: J
authors: J
authors: Takahashi
authors: S
authors: S
authors: Kondoh
authors: M
authors: M
authors: Matsumoto
authors: T
authors: T
authors: Yamasaki
authors: K
authors: K
authors: Iwasaki
authors: T
authors: T
authors: Aoki
mesh_terms: D000943:Antigens, Differentiation / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D017252:CD3 Complex; D002469:Cell Separation; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000628:therapy*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D011961:Receptors, Fc / Q000032:analysis; D017452:Receptors, IgG; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
chemical_list: D000943:Antigens, Differentiation; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D015395:Histocompatibility Antigens Class I; D011948:Receptors, Antigen, T-Cell; D011961:Receptors, Fc; D017452:Receptors, IgG; D011994:Recombinant Proteins; D007371:Interferon-gamma